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ABSTRACT 
Parkinson’s disease (PD) has long been conceptualized as a motor disorder, but 
significant clinical features arise before motor symptoms are present. Although 
prospective, longitudinal research offers the most valid approach for determining pre-
diagnostic indicators of PD, it is costly and requires a long time-course. Leveraging 
existing epidemiological datasets offers the opportunity to identify pre-diagnostic 
features that may predict later PD diagnosis. 
This project used the Framingham Heart Study (FHS) database of prospective 
follow-up on a community-based sample that spans over six decades. Regular 
surveillance identified 156 incident cases of PD. Promising biomarker and other clinical 
marker candidates were derived from cohort-based samples without prospective follow-
up and included cognition, depression, and inflammation. The main hypothesis was that 
potential markers would discriminate between individuals who did/ did not go on to a 
later PD diagnosis. The FHS database provided clinical markers (cognition, depression) 
and fluid biomarkers (levels of plasma inflammation) for interrogation. Cognition was 
	
	 vii 
indexed by performance on the Mini-Mental State Examination and a comprehensive 
neuropsychological assessment, including measures of attention, memory, and executive 
functioning. Depression was derived from scores on the Center for Epidemiologic Studies 
Depression Scale (CES-D). Separate means comparison and logistic regression analyses 
to maximize sample sizes were conducted on available data for candidate (bio)markers at 
time-points 1-3 years or 1-5 years pre-diagnosis for PD cases (N=7-33) and control 
participants (N=28-224), in samples matched for age, sex, and education level. 
No significant differences were found between PD and control participants on any 
measure of cognitive functioning 1-3 years pre-diagnosis. No significant differences were 
found for total CES-D scores or levels of plasma inflammation 1-5 years pre-diagnosis. 
Higher levels of C-reactive protein and TNF-alpha were significantly correlated with 
increasing age in the total sample but not for PD specifically. 
These results indicate that cognition, self-reported depression, and plasma 
inflammation may not be useful as markers of PD risk, and efforts should likely focus on 
alternative candidate markers. Detecting PD in the earliest stages is an important goal, as 
it could lead to treatments that attenuate progression, improve clinical prognosis, and 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
Parkinson’s disease (PD) has been characterized as a movement disorder since its 
initial description over 200 years ago by James Parkinson in his An Essay on the Shaking 
Palsy (Parkinson, 2002). It is diagnosed on the basis of motor symptoms including 
bradykinesia, tremor, rigidity, and disturbances of posture, balance, and gait, which 
follow from degeneration of dopaminergic neurons in the substantia nigra of the midbrain 
and subsequent basal ganglia dysfunction (de Lau & Breteler, 2006). In recent years, it 
has become understood that a period of neurodegeneration begins well before the 
emergence of motor symptoms in this disease. This pre-diagnostic phase is characterized 
by features that could potentially identify those who will eventually convert to clinical 
PD. Many of these features are non-motor symptoms, which challenges our 
understanding of the diagnosis and progression of PD. 
The neuropathology of PD has been well characterized by dopaminergic loss in 
the striatum and related disruption of the basal ganglia and associated motor circuits 
(Rodriguez-Oroz et al., 2009). Distinctive inclusion aggregates composed of alpha-
synuclein develop into globular Lewy bodies and spindle-like Lewy neurites that affect 
vulnerable neurons (Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004; Obeso, 
Rodriguez-Oroz, Rodriguez, Arbizu, & Gimenez-Amaya, 2002). Braak and colleagues 
have described this neuropathology as a series of six stages beginning in the brainstem 
medulla oblongata and pontine tegmentum and in olfactory areas (stages 1 & 2, 




neocortex (stages 5 & 6) (Braak et al., 2003; Braak, Ghebremedhin, Rub, Bratzke, & Del 
Tredici, 2004). By the time the neuropathology has affected the substantia nigra and 
motor symptoms emerge, up to 80% of the dopaminergic neurons have already been 
depleted (Braak & Del Tredici, 2008). Identifying the earliest phases of PD has important 
clinical and research implications. Screening for a disease before overt symptoms are 
evident is emerging as a standard approach because of the potential increased 
effectiveness of early intervention (Siderowf & Lang, 2012). Being able to detect the 
disorder in the earliest stages, before motor symptom onset, may lead to treatments that 
significantly slow progression, improve prognosis, and allow the opportunity for 
prevention.  
Recent work into the early disease phase has expanded our understanding of the 
neuropathological progression in PD. Some individuals with PD have been found to have 
alpha-synuclein deposition occurring earlier in the substantia nigra, while others may 
have deposition in the amygdala and cortex prior to the brainstem (Parkkinen, Pirttila, & 
Alafuzoff, 2008; Sulzer & Surmeier, 2013). Alternatives to the Braak staging model have 
been proposed, including one in which the olfactory system is first affected, followed by 
divergent paths affecting either the limbic areas or lower brainstorm before converging in 
the upper brainstem and cortex (Adler & Beach, 2016). There is also increased 
appreciation that early pathology begins in non-dopaminergic structures in the brain and 
the peripheral nervous system; some have postulated that pathology in PD spreads in a 
prion-like fashion, with alpha-synuclein deposition beginning in the gut and moving 




Reichmann, 2015). Understanding that alpha-synuclein deposition begins outside the 
substantia nigra (and possibly outside the brain) is key to understanding the non-motor 
features that characterize early PD.  
Individuals with PD exhibit extensive heterogeneity in disease presentation, motor 
and non-motor symptomatology, and rates of progression, leading many investigators to 
examine for disease subtypes. These groups have been classified through an 
observational approach of clinical symptoms and data-driven approaches employing 
cluster analysis without a priori hypotheses. Researchers have used predominance of 
specific motor symptoms, age of disease onset, laterality of symptoms, disease severity, 
cognitive performance, and several other categories to define subtypes of PD (Marras & 
Lang, 2013). Motor symptoms have driven much of the research on disease subtyping, 
with the most common being tremor-dominant versus postural instability and gait 
disorder dominant or akinetic-rigid dominant (Nutt, 2016). More men than women are 
diagnosed with PD, and gender differences have been reported that may interact with 
other symptoms (Miller & Cronin-Golomb, 2010). Examining PD subtypes can reveal 
differences in a number of factors that go beyond typical symptoms, including 
differences in quality of life and activities of daily living (Appleman, Stavitsky & Cronin-
Golomb, 2011; Seichepine et al., 2011). 
In recent years, research on the heterogeneity of non-motor symptoms has been 
growing (Marras & Chaudhuri, 2016). Viewing PD as a disconnection syndrome may be 
useful for explaining differences that arise in subtypes of PD and subsequent effects on 




2010). One study reported a high burden of non-motor symptoms in early or treatment 
naïve PD despite mild motor disability, suggesting that non-motor symptoms may be 
important in identifying differences in the pre-diagnostic phases of PD (Zis, Erro, 
Walton, Sauerbier, & Chaudhuri, 2015). Work in this area has concurrently attempted to 
identify biomarkers to better understand the neuropathological underpinnings related to 
these differences, going so far as to view PD as a group of disorders rather than a single 
complex disease (Espay et al., 2017). This viewpoint takes lessons from oncology 
research in hopes of preparing the field to be successful with future disease modifying or 
neuroprotective therapies in PD. 
 
Defining Pre-Diagnostic PD 
In light of advancing knowledge related to neuropathological progression and 
non-motor symptoms of PD, a task force of the Movement Disorder Society has moved 
to reconsider the definition of PD and better define the early period of the disease. This 
work has postulated three phases of disease development: the preclinical, prodromal, and 
clinical phases of PD (Berg et al., 2014). 
The task force proposed the following definitions for the three phases. In the 
preclinical phase, neurodegenerative synucleinopathy has begun but symptoms are 
absent; diagnosis at this stage would require valid and reliable (bio)markers of PD, which 
are not yet available. The prodromal phase is defined by clinical symptoms or signs of 
neurodegeneration seen on neuroimaging, but the individual does not meet current 




define PD today. Further work has begun to synthesize the current state of the literature 
on the prodromal stage of PD. Specific research criteria for the prodromal phase of PD 
were proposed in 2015 (Berg et al., 2015) and were based on the likelihood of prodromal 
disease with greater than or equal to 80% certainty using a Bayesian naïve classifier 
procedure. This involves comparing probability of PD development based on age to 
probability of PD based on diagnostic information, which includes both background risk 
from environmental risk factors and genetic findings as well as diagnostic marker testing. 
These diagnostic markers include both motor and non-motor clinical symptoms, signs, 
and ancillary tests, such as neuroimaging. Markers were assigned positive likelihood 
ratios based on the research literature to indicate increased risk of prodromal PD, while 
absence of these markers was assigned negative likelihood ratios indicative of reduced 
risk. The likelihood ratios for each marker are combined to calculate overall risk of 
prodromal PD for each specific individual.  
Background risk markers identified in the report on research criteria included 
male sex, regular pesticide exposure, occupational solvent exposure, nonuse of caffeine, 
having never smoked, relative status (sibling or other first degree relative with PD), 
known gene mutation, and substantia nigra hyperchogenicity (increased amplitude of 
waves returned during ultrasonography of the substantia nigra). Prodromal markers from 
diagnostic marker testing included polysomnography-documented rapid eye movement 
sleep behavior disorder (RBD) or positive RBD screen questionnaire with >80% 
specificity, clearly abnormal dopaminergic positron emission tomography (PET)/single 




olfactory loss, constipation, excessive daytime somnolence, severe erectile dysfunction, 
urinary dysfunction, and depression with or without anxiety. 
Although a number of risk and prodromal markers have been identified, there are 
limitations to the proposed model and significant room for improvement in the evidence 
base (Berg et al., 2015). Most importantly, there is a paucity of research using 
prospective studies that examine conversion to PD in representative samples. 
Additionally, the independence of various markers and the duration of the appearance of 
each prior to conversion is unknown; even for well-documented markers, there is 
significant variability in the strength of predictive values over time. There is little 
consensus on clear cut-offs for what distinguishes abnormal values on individual tests, 
and the predictive value of individual markers may vary across sex, age, disease subtype, 
or other factors.  
Given the heterogeneous nature of PD, it is implausible that a single factor will 
emerge with the power to independently reliably identify those who will convert to PD 
from the general population. Rather, a complex combination of factors will likely provide 
the most comprehensive understanding of risk. Future success may require using a data-
driven and translational approach, including the employment of technology-driven 
symptom identification and machine learning techniques to improve the predictive value 
of this research scaffold. 
	
Pre-Diagnostic Factors of Interest 




factors, much more work remains to be done to determine how potential factors 
independently and in combination may contribute to the development of PD. Three 
factors of interest include cognition, depression, and plasma inflammation. Research has 
demonstrated changes in each of these areas throughout the course of PD, with recent 
studies focusing on the early phase of PD in particular. 
 
Cognition  
There is marked heterogeneity in the neuropsychological deficits that have been 
described in PD. Although cognitive changes were traditionally described as occurring 
later in the disease process, multiple samples have suggested that up to 40% of 
individuals with incident, untreated PD may exhibit cognitive impairment in one or more 
domains of functioning including attention, working memory, executive functioning, 
visuospatial skills, language, or episodic memory (Papagno & Trojano, 2018). These 
numbers are, of course, highly dependent on how cognitive dysfunction is defined. 
Identifying the onset of cognitive changes in PD is an ongoing challenge for 
researchers and difficult to measure without the use of prospective longitudinal trials. 
One study examined decline in scores over a three-year follow-up on the Mini-Mental 
State Examination (MMSE) for individuals with prevalent (untreated) PD, pre-motor PD 
(converters over follow-up), and control participants (Sanchez-Ferro et al., 2013). They 
reported a significant difference in rate of decline for prevalent PD and controls, but not 
pre-motor participants and control, concluding that declining global cognition may not be 




extensive evaluation of both cognition and PD symptomology reported significant 
differences in pre-diagnostic PD cases when compared to age and sex-matched control 
participants for a number of cognitive tasks (Darweesh et al., 2017). The use of cognition 
as a marker for pre-diagnostic PD remains an open research question.  
 
Mood  
Neuropsychiatric symptoms including anxiety, depression, apathy, and 
hallucinations are some of the most commonly reported non-motor features of PD 
(Szatmari et al., 2017). PD pathology in the raphé nuclei and locus coeruleus at Braak 
stage 2 supports the observation that mood disturbance may be a pre-diagnostic symptom 
of PD. There is growing evidence examining depression, anxiety, apathy, impulse control 
disorders, and psychosis in early, untreated PD, with depression being among the more 
well-studied of these symptoms. 
A number of population-based studies have provided evidence for the use of 
depression as a prodromal feature of PD (Schrag, Horsfall, Walters, Noyce, & Petersen, 
2015; Leentjens, Van den Akker, Metsemakers, Lousberg, &Verhey, 2003; Alonso, 
Rodríguez, Logroscino, Hernán, 2009; Fang et al., 2010; Gustaffsson, Nordström, & 
Nordström, 2015). These studies have primarily used data taken from electronic health 
record coding (e.g. depression diagnoses or use of antidepressants). The use of self-
reported depressive symptoms as a prodromal marker is less well-studied, although a 
recent study using the Center for Epidemiologic Studies Depression Scale (CES-D) 




converted to PD (Darweesh et al., 2017). While a solid research base exists for the 
consideration of depression in PD risk, more work remains to be done to address the 




 Inflammation has been identified as another potential marker for pre-diagnostic 
PD and it may serve as a potential link between the two previously described markers and 
the development of PD. Concurrent research has separately implicated inflammatory 
processes in the development of both cognitive impairment and depression in older adults 
(Gorelick 2010; Dowlati et al., 2010). Researchers have reported elevated levels of 
certain inflammatory cytokines in both cerebrospinal fluid and plasma in post-mortem 
and clinical human studies of PD (Nagatsu & Sawada, 2005; Dobbs et al., 1999; Dufek et 
al., 2009); however, no marker has reached sufficient sensitivity or specificity to be 
considered to be a diagnostic marker of PD (Postuma et al., 2015). There is a paucity of 
research using longitudinal samples that allow the examination of inflammatory levels 
during the pre-diagnostic phase of PD. 
 
Specific Aims and Hypotheses 
The three studies presented here were designed to evaluate the utility of three 
proposed markers of pre-diagnostic PD: cognition, depression, and plasma inflammation, 




Study One: Cognition as a Marker of PD  
Despite cognitive impairment traditionally being viewed as a later symptom of the 
disease, mild cognitive changes have been reported in multiple samples of incident, 
untreated PD (Lawson et al., 2016, Aarsland 2016; Weintraub et al., 2015). The timing 
and nature of cognitive changes in PD is unknown, and the utility of cognition as a pre-
diagnostic marker is controversial. Sánchez-Ferro and colleagues (2013) reported no 
differences in scores on the MMSE for participants who went on to develop PD two to 
three years after testing. By contrast, the prospective Rotterdam study reported significant 
differences in pre-diagnostic PD cases when compared to age and sex-matched control 
participants for a number of cognitive tasks (Darweesh et al., 2017). Study 1 of the 
present project examined MMSE scores and neuropsychological test performance in 
individuals with PD before their diagnosis and compared the performance to that of 
matched healthy control adults. Pre-diagnostic testing aimed to capture individuals during 
the pre-clinical Stage 1 and 2 of the Braak staging of neurodegeneration in PD. At this 
point pathology (presence of Lewy bodies and Lewy neurites) may be evident low in the 
brainstem (medulla oblongata, pontine tegmentum) and olfactory areas, and may 
contribute to deficits on tasks requiring attention and arousal. Other neuropsychological 
tasks that require higher cognitive functions such as executive function and memory were 
not hypothesized to be significantly affected until after PD diagnosis and Braak stages 5 






Study Two: Depression as a Marker for PD.  
In recent years, depression has emerged as an important component of the 
research criteria for pre-diagnostic Parkinson’s disease (Berg et al., 2015). The goal of 
Study 2 was to replicate the previously described population-based studies in another 
epidemiologic sample representative of a general population. Additionally, this study 
aimed to examine evidence for the utility of the CES-D questionnaire. Although this 
questionnaire is not specific to PD, it is commonly utilized in large prospective-based 
epidemiologic studies and evaluating it here would inform other trials that may wish to 
evaluate PD risk, either by examining previously collected data in those already using the 
CES-D or including it in future trial design. It was hypothesized that individuals who 
went on to develop PD would have higher depression scores pre-diagnosis when 
compared to the control group.  
 
Study Three: Inflammation as a Marker for PD. 
Objectively measured plasma biomarkers would provide a potentially cost-
effective and less invasive marker for pre-diagnostic PD in comparison to those obtained 
through genetic screening, neuroimaging, or cerebrospinal fluid samples. Examining the 
role of inflammation in PD may also improve our understanding of other non-motor 
symptoms of the disease, including depression and cognition. While some candidates 
have been evaluated, there is overall a paucity of research on plasma inflammatory 
markers of PD in pre-diagnostic samples. The goal of Study 3 was to conduct an 




large epidemiologic sample. It was hypothesized that individuals who went on to develop 
PD would have higher levels of available inflammatory markers pre-diagnosis than the 
control group.  
 
Significance 
Interest in identifying markers of the pre-diagnostic phase of PD has led to a call 
for prospective, longitudinal study designs to identify at-risk populations (Berg & Poewe, 
2012). This methodology offers the most valid approach but is also costly and requires a 
long time-course. A recent review of longitudinal studies addressing pre-diagnostic 
markers of PD discussed a number of limitations in this literature including weaknesses 
of study design, sample size, assessment of PD diagnosis and biomarkers, and variability 
in the time before diagnosis at which eventual conversion could be predicted (Heinzel et 
al., 2016). 
The present research project proposed to advance the study of the pre-diagnostic 
phase of PD, with the goal of evaluating the role of several clinical markers: cognition, 
depression, and plasma inflammation. These studies capitalized on the existing database 
of the Framingham Heart Study (FHS), with its rigorous prospective follow-up of a large 
community-based sample that spans over six decades. Although studies of at-risk 
individuals provide value in maximizing sample sizes because they generally result in 
higher levels of conversion to PD, these samples are generally less representative of the 
overall spectrum of pre-diagnostic PD. They may instead represent the characteristics of 




risk factor for it) and overlook features that apply to other individuals who develop PD 
but lack a specific risk factor. 
First, the results of Study 1 added to the limited data on cognitive changes that 
occur pre-diagnosis. To the best of our knowledge, this is one of the only community-
based samples of PD that looked at a comprehensive neuropsychological assessment of 
Parkinson’s disease pre-diagnosis. Second, the results of Study 2 added to the already 
strong literature on the use of depression as a clinical marker of PD. Although this 
finding has been reported in other studies that used diagnosis of depression from medical 
records or use of antidepressants as risk factors, the present study used self-reported 
depressive symptoms, which could be an important feature of pre-diagnostic PD. One 
recent study suggests that rates of self-reported depression are higher pre-diagnosis 
(Darweesh et al., 2017). Finally, the results of Study 3 provided needed information on 
plasma biomarkers available pre-diagnosis in PD. To date, there had been no consistent 
findings available for any plasma markers of inflammation, despite these relations being 











As described in the previous chapter, Parkinson’s disease (PD) is a progressive 
neurodegenerative disorder clinically diagnosed by the presence of specific motor 
symptoms, but a number of clinical features have been identified as occurring during a 
prodromal phase (Berg et al., 2014). Identifying a pre-diagnostic phase of PD has 
important clinical and research implications because of the potential increased 
effectiveness of early intervention (Siderowf & Lang, 2012). Being able to detect the 
disorder in the earliest stages, before motor symptom onset, may be critical for trials of 
neuroprotective therapy. 
Formal research criteria for pre-diagnostic PD were recently published, 
combining estimates of risk from environmental factors and genetic findings with the 
results of various diagnostic marker testing including motor and non-motor clinical 
symptoms, clinical signs, and ancillary diagnostic tests (Berg et al., 2015). REM Sleep 
Behavioral Disorder, olfactory loss, and constipation are non-motor symptoms with the 
strongest evidence for conversion to PD (Postuma & Berg, 2016). Other non-motor 
factors have more moderate evidence and include aspects of autonomic dysfunction such 
as orthostatic hypotension, urinary dysfunction, and erectile dysfunction, visual changes, 
and somnolence (Postuma & Berg, 2016). While cognitive impairment has often been 




some evidence for changes occurring prior to diagnosis (Postuma & Berg, 2016).  
As previously described, according to the Braak staging system, neuropathology 
in PD is characterized by the progressive loss of dopaminergic neurons and alpha-
synuclein deposition that spreads from brainstem and midbrain structures to higher-level 
cortical areas (Braak et al., 2003; Braak & Del Tredici, 2008). Cognitive dysfunction in 
PD has been related to Lewy body pathology in limbic and cortical regions, with 
potential contribution from Alzheimer’s disease-like changes such as amyloid 
pathologies and tau-based inclusions, as well as neurotransmitter changes in cholinergic 
and glutamatergic systems (Aarsland, 2016). More advanced dementia in PD is 
characterized by a reduction in cortical cholinergic markers, as well as increased effect on 
dopaminergic and serotonergic systems (Lewis, Dove, Robbins, Barker, & Owen 2003; 
Rinne et al., 2000; Chan-Palay & Asan, 1989). 
Barker and Williams-Gray (2014) proposed two different early cognitive profiles 
in PD – frontal executive impairments, originating from fronto-striatal malfunctioning 
and dopamine depletion in the striatum and frontal lobes, contrasted with posterior 
cortical impairments, originating from cortical Lewy bodies and not associated with 
deficits in dopamine. The authors posited that posterior cortical deficits would be 
predictive of dementia. A recent review examining evidence for pathological, genetic, 
PET imaging, task-based, anatomical, and resting-state functioning connectivity 
functional Magnetic Resonance Imaging (fMRI) concluded that the literature has 
identified heterogeneous pathological processes leading to cognitive decline in PD and 




classification of stages of PD neurodegeneration would predict that the earliest cognitive 
changes may occur in the domains of attention and arousal, arising from early pathology 
in the lower brainstem. Lewy body deposits begin in the pons and brainstem and progress 
to the neocortex, a process that may advance in parallel with cognitive decline (Braak, 
Rüb, Jansen Steur, Del Tredici, & De Vos., 2005).  
In a study of individuals with mild to moderate PD with neither dementia nor 
Mild Cognitive Impairment (MCI), measures of attention and executive function (frontal-
type tests) were the most sensitive to cognitive compromise (Miller, Neargarder, Risi, & 
Cronin-Golomb, 2013). Visuospatial, attentional, and executive deficits are the most 
typical cognitive deficits seen in individuals with MCI (Aarsland, Brønnick, & Fladby, 
2011). Dementia is prevalent in later disease stages and risk factors for transition from 
MCI to Parkinson’s disease dementia include increased age, motor symptom severity, 
predominately bradykinetic/rigid form of PD, and visual hallucinations (Papagno & 
Trojano, 2018). Additionally, early cognitive deficits may predict the progression of 
cognitive dysfunction to dementia (Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 
2003; Kehagia, Barker, & Robbins, 2010; Levy et al., 2002; Williams-Gray et al., 2009; 
Williams-Gray et al., 2007). Later onset dementia in PD is characterized by visuospatial 
and constructional deficits as well as problems with semantic and episodic memory 
(Schapira, Chaudhuri, & Jenner, 2017). 
Multiple samples have reported cognitive deficits in incident, untreated PD, and 
rates are highly dependent on how cognitive impairment is defined, although studies have 




domain (Rosenthal et al., 2010; Foltynie et al., 2004, Elgh et al., 2009; Aarsland et al., 
2009). Formal criteria for MCI in PD (PD-MCI) defined by the Movement Disorder 
Society (MDS) (Litvan et al., 2012) have improved recent research design, though 
inconsistent findings remain. These criteria specify that five cognitive domains should be 
included in an assessment of cognitive performance in PD: attention and working 
memory, executive functions, visuospatial skills, long-term memory, and language. An 
abbreviated level 1 assessment would include at least one test in each cognitive domain, 
and PD-MCI would require impairment on at least two tasks across domains. A more 
stringent level 2 assessment would include at least two measures for each domain, and 
PD-MCI would require at least two impaired tests within a single domain or one impaired 
test in two different domains. For both levels, a diagnosis of PD-MCI would also require 
individuals to show declining cognition with preserved functional independence. 
Between 15 and 20% of individuals with de novo PD have been reported as 
meeting criteria for MCI using a variety of definitions (Aarsland, 2016). One recent study 
of a sample of 212 participants with PD reported that 21% met the formalized MDS 
MCI-PD criteria at baseline (Lawson et al., 2016). By contrast, data from the longitudinal 
Parkinson’s Progressive Markers Initiative (PPMI) indicated that fewer than 1% of 
participants met these criteria, primarily due to the low frequency of cognitive decline 
reported by investigators (Weintraub et al., 2015). In this sample, 22% met the 
recommended screening cut-off for PD on the Montreal Cognitive Assessment (MoCA), 
and 9% met neuropsychological testing criteria for MCI. Little work has been done using 




The availability of longitudinal data to identify the onset of cognitive changes in 
PD is rare. Instead, many current trials have enrolled participants at high risk for eventual 
conversion to PD. Early reports from the Tübinger Evaluation of Risk Factors for Early 
Detection of Neurodegeneration Study (TREND) reported that self-reported forgetfulness 
and word-finding difficulty were the most commonly reported NMS in those with high 
risk for PD, due to presence of hyposmia and RBD (Gaenslen, Swid, Liepelt-Scarfone, 
Godau, & Berg, 2014). The PREDICT-PD study created a PD risk score using results 
from an online questionnaire, computerized typing task, and the University of 
Pennsylvania Smell Identification test, and found that scores for the MoCA screening 
measure were somewhat lower for high-risk than low-risk participants (Noyce et al., 
2017). The Parkinson Associated Risk Syndrome (PARS) study reported that participants 
at high risk for PD due to the presence of hyposmia and reduced dopamine transporter 
binding had lower mean scores for global cognition, executive functioning/working 
memory, and memory when compared to those without those risk factors (Chahine et al., 
2016). Prospective follow-up for this study, as well as others, is still pending. 
Case-control studies of patient registry or medical system data have also 
attempted to examine the relation between cognition and development of PD, reporting 
associations between “non-specific cognitive impairment without functional limitation or 
dementia” (O’Sullivan et al., 2008), presence of mental and behavior disorder diagnoses 
(Frandsen, Kjellberg, Ibsen, & Jennum 2014), and incidence of memory problems as 
reported by a clinician (Schrag, Horsfall, Walters, Noyce, & Petersen, 2015) as related to 




Population-based prospective cohort studies are extremely limited. Sánchez-Ferro 
and colleagues (2013) reported no significant difference in rate of declining Mini Mental 
State Examination (MMSE) scores for pre-motor PD participants (those who converted to 
a PD diagnosis over 2-3 year follow-up) in comparison to control participants in the 
Neurological Disorders in Central Spain (NEDICES) cohort. The Honolulu-Asia-Aging 
Study (HAAS) used the Cognitive Abilities Screening Instrument and found that scores 
were not associated with incidence of PD, although they did show some association 
between lower executive performance and development of PD (Ross, Abbott, Petrovich, 
Tanner, & White, 2012). A small prospective study that identified five converters to PD 
over a 5-year period reported reduced MMSE scores for these participants, as well as 
lower scores on a naming task, word list encoding, copying and free recall, and a 
cognitive composite (Pausch et al., 2016). A recent report with a much larger sample 
from the prospective Rotterdam study reported significant differences in pre-diagnostic 
PD cases when compared to age and sex-matched control participants on the MMSE 
(Darweesh et al., 2017). Scores on the MMSE significantly diverged at 5.6 years pre-
diagnosis in this sample. This study included a more comprehensive evaluation of both 
PD symptoms as well as cognitive functioning over time. Scores on a version of the 
Symbol Digit Modalities Test showed the earliest significant difference between 
converters and control participants, at 7.1 years pre-diagnosis. This was followed by 
worse scores on the three Stroop tasks (6.2-3.8 years depending on task) and the Word 
Fluency Test (3.3 years). Despite the differences seen on these objective measures, 




complaints until 1.5 years pre-diagnosis.  
More work is needed to better understand cognitive change in the pre-diagnostic 
phase of PD, and longitudinal samples with data available at this stage will provide the 
best resources to further this work. Pre-existing large-scale epidemiologic studies can 
offer the opportunity to maximize the value of already collected data and assist in 
answering questions about specific domains affected and timing of cognitive changes. 
The current project aimed to capitalize on the Framingham Heart Study’s (FHS) 
rigorous prospective follow-up of a community-based sample. This project compared 
cognitive performance of individuals before their eventual PD diagnosis to performance 
of matched healthy control adults from the overall FHS sample, corrected for time 
between testing and diagnosis. In FHS, cognitive performance is examined with a global 
screening measure, the MMSE, as well as with comprehensive neuropsychological 
assessment of individual cognitive domains. Pre-diagnostic testing may capture 
individuals during the pre-clinical Stage 1 and 2 of the Braak staging of 
neurodegeneration in PD. At this point in the disease course, pathology (presence of 
Lewy bodies and Lewy neurites) may be evident low in the brainstem (medulla 
oblongata, pontine tegmentum), which may contribute to deficits on tasks requiring 
attention and arousal. Other neuropsychological tasks that require higher cognitive 
functions such as executive function and memory may not be significantly affected until 
Braak stages 5 and 6, which are after PD diagnosis (that is, after the emergence of the 
motor symptoms that lead to the diagnosis of the disease). Recent research has suggested 




measures of global cognition are mixed (Fengler et al., 2017). This calls into question our 
understanding of neurodegeneration in PD and more work needs to be done in this area. 
In accordance with the areas affected by pathology at the various stages of the 
course of PD, the main hypothesis of this study was that individuals who eventually 
developed PD (defined by appearance of motor symptoms) would, on pre-diagnosis 
neuropsychological testing, be unimpaired on the MMSE and on tests that rely primarily 
on executive function and memory because these depend on higher-order cortical areas, 
the integrity of which would be preserved at that early stage. By contrast, because of pre-
diagnostic pathology in lower brainstem, this group of individuals would possibly exhibit 




The FHS Original cohort (Generation 1 [Gen 1], n=5209) has been followed 
prospectively since enrollment in 1948 to investigate the risk factors for cardiovascular 
disease and stroke. The Offspring cohort (Gen 2, n=5124) was enrolled in 1971 and 
comprises the children and spouses of Gen 1 participants. In 2002, the grandchildren of 
Gen 1 and children of Gen 2 were enrolled as the Gen 3 cohort (n=4105). Additionally, to 
reflect growing racial and ethnic diversity in the Framingham area, a multi-ethnic Omni 
cohort (Omni-Gen 1; n=500) was recruited in 1990. Their children were recruited in 2003 
to comprise Omni-Gen 2 (n=410). Each cohort group undergoes regular clinical 




previous exam (including hospitalizations), a panel of blood tests, MMSE, a series of 
questionnaires including the Center for Epidemiological Studies Depression Scale (CES-
D), and a 12-lead electrocardiogram. These exams occur approximately every two years 
for Gen 1 participants and approximately every four years for Gen 2 participants. 
Ancillary studies have been implemented to follow participants for additional health 
outcomes including stroke, dementia, osteoporosis, sleep, and other conditions, such as 
PD. The present sample consisted of participants from Gen 1 and Gen 2 who had also 
completed cognitive assessments over the course of participation in the study. The study 
protocol was approved by the Boston University Institutional Review Board, with 
consent obtained according to the Declaration of Helsinki. 
 
Participants 
FHS reviews the data of participants with suspected PD during regular consensus 
meetings. Individuals are flagged for review from a number of sources, including 
participant report at clinical exams, medical record review mentioning PD-related 
symptoms, or referral from neuropsychological assessment visits. The review process 
includes careful assessment of all FHS clinical examinations and outside medical records 
by a team including at least one neurologist to determine whether individuals flagged for 
potential PD meet UK Brain Bank criteria for diagnosis (Hughes, Daniel, Kilford, & 
Lees, 1992).  
The study sample included 33 individuals diagnosed with PD who had had 




FHS sample made it possible to identify three healthy control participants matched to 
each participant with PD, which maximized statistical power. The 99 control participants 
were matched to the PD group on demographic variables including age, sex, and 
education level. Apolipoprotein E (ApoE) status (the presence of one or two Apo ε4 
alleles) and cardiovascular risk factors were also considered. These factors have been 
shown to significantly interact with the development of cognitive impairment (Gupta et 
al., 2015; Elias, Elias, D’agostino, Silbershatz, & Wolf, 1997). Demographic information 
is reported in Table 1. 
 
Table 1. Demographic characteristics of PD cases and matched control sample for cognitive analyses. 
 PD Cases (n=33) Control Group 
(n=99) 
Age, years 80±8 81±8 
Men, n (%) 18 (55%) 54 (55%) 
Interval between exam and cognitive 
testing, years 
0.52±0.69 0.57±1.30 
Education, n (%)* 














Systolic blood pressure (mmHg) 141±22 140±21 
Apolipoprotein E ε4 genotype, (%) 7 (28%) 18 (24%) 
Total cholesterol, mg/dl 188.2±30.2 195.6±32.9 
Antihypertensive medication, n (%) 13 (39.4%) 44 (45.4%) 
Diabetes mellitus, n (%) 2 (7.4%) 12 (14.8%) 
Current smoking, n (%) 1 (3.1%) 6 (6.2%) 
Prevalent cardiovascular disease, n (%) 7 (21.2%) 38 (38.4%) 
Prevalent atrial fibrillation, n (%) 4 (12.1%) 17 (17.2%) 
Left ventricular hypertrophy 2 (6.1%) 3 (3.3%) 






All participants were administered the MMSE and a comprehensive 
neuropsychological assessment. The neuropsychological assessment uses original 
versions of tests to facilitate longitudinal and intergenerational comparisons. The 
neuropsychological assessment was administered using standard protocols and trained 
examiners; details related to the Gen 1 and Gen 2 cohorts are published (Elias, Elias, 
D’agostino, Silbershatz, & Wolf, 1997; Au et al., 2004). The neuropsychological 
assessment included tasks in the domains of attention and working memory, verbal 
memory, visual memory, executive functioning, abstract reasoning, and motor 
functioning. Details of the cognitive tasks used for this study are reported in Table 2. 
 
Table 2. Neuropsychological assessment measures used for cognitive analyses. 
Cognitive Domain Neuropsychological Test Measures Defined  
Attention Trail Making Test A and Test B 
 WMS Digit Span Forward & Backward 
Executive Function Controlled Word Association Test (FAS) 
 Trail-Making Test B 
Verbal Memory WMS Logical Memory Immediate Recall 
 WMS Logical Memory Delayed Recall 
Visual Memory WMS Visual Reproductions – Immediate Recall 
 WMS Visual Reproductions – Delayed Recall 
Abstract Reasoning WAIS – Similarities subtest 
Motor Functioning Finger Tapping Test 
 
The Trail Making Test (TMT) (Tombaugh, 2004) was given to evaluate attention, 
set-shifting, and executive functioning. The test requires the participant to quickly draw 
lines that connect numbers in ascending order (TMT-A), or that alternate between 




completion. A derived TMT difference score was calculated (TMT-B – TMT-A), which 
removed the psychomotor component of the task that is captured in TMT-A (O’Rourke et 
al., 2011). The Digit Span subtest from the Wechsler Memory Scale (WMS) was also 
given to assess attention (Forward and Backward conditions) and working memory 
(Backward condition). Score for each was the total number of correct trials. Executive 
function was assessed using the Controlled Word Association Test (FAS), in which 
participants were asked to name as many unique words beginning with the letters F, A, 
and S as quickly as possible. The time limit for each trial was 60 seconds, and the total 
score was the total number of correct responses summed across the F, A, and S trials. 
Verbal memory was assessed with the Wechsler Memory Scale Logical Memory 
subtest, in which participants had to repeat a short story immediately following verbal 
presentation (Immediate Recall) and after a 15-20 minute delay (Delayed Recall). Score 
for each was total number of correctly recalled story details. Similarly, visual memory 
was assessed with the Wechsler Memory Scale Visual Reproductions subtest, in which 
participants had to draw a series of geometric figures immediately following a brief (10 
second) presentation (Immediate Recall) and after a 15-20 minute delay (Delayed 
Recall). Score for each was based on total number of correctly recalled figure details. 
Abstract reasoning was assessed using the Similarities subtest from the Wechsler 
Adult Intelligence Scale (WAIS) in which participants had to describe how two items 
(e.g., an orange and a banana) were alike. Total score was based on manual and site-
specific norms for classifying participant responses. 




participants are instructed to use their index finger to repeatedly tap a metal lever as 
quickly as possible. There were 10-second trials, alternating between dominant and non-
dominant hands until a stable score was reached for each hand (5 trials within 5 taps of 
each other). Total score was calculated as the average of 5 consistent trials for dominant 
and non-dominant hands.  
 
Data Analysis  
PD cases were compared to matched control participants for MMSE total score 
and each neuropsychological variable score as described above. Education level 
significantly differed between groups, which was subsequently controlled for in all 
analyses. A p-value of <0.05 was considered to be significant. Values for MMSE and 
Trails A and B were expressed as median with 1st and 3rd quartiles, rather than mean and 
standard deviation to normalize the skewed distribution.  
 
Results 
A total of 156 individuals in Gen 1 and Gen 2 of FHS participants were identified 
as having a diagnosis of PD according to previously described criteria. Average age at 
diagnosis was 77.4 (SD=9.5) for Gen 1 participants and 73.5 (SD=9.6) for Gen 2 
participants, which is higher than the average age of 62 quoted by the National Parkinson 
Foundation but is consistent with that reported in the Rotterdam study (mean age = 78; 
SD = 7). A total of 33 individuals in the FHS sample had completed MMSE and 




was 80 years (SD = 8). Cognitive performance was not significantly different for men 
and women.  
There were no significant differences found between control participants and PD 
cases for either the total MMSE score or any of the neuropsychological test scores. Table 
3 summarizes performance on all tasks for PD cases and the control group. 
 
Table 3. Comparison of scores for neuropsychological assessment measures in cases (1-3 years before PD 
diagnosis) and control group. 
 PD cases  Control group 
Trails A, median (q1,q3) 0.7 (0.6, 0.9) 0.8 (0.5, 1.1) 
Trails B, median (q1,q3) 2.2 (1.7, 2.9) 1.9 (1.2, 3.1) 
Trails B - Trails A, median (q1,q3) 1.4 (0.9, 2.1) 1.1 (0.6, 2.3) 
Digit Span Forward 6.3 (1.3) 6.1 (1.4) 
Digit Span Backward 4.3 (1.3) 4.2 (1.5) 
Logical Memory, Immediate Recall 8.2 (4.9) 8.1 (4.8) 
Logical Memory, Delayed Recall 7.8 (5.9) 7.1 (5.1) 
Visual Reproductions, Immediate Recall 5.4 (3.5) 5.8 (3.7) 
Visual Reproductions, Delayed Recall 4.7 (4.0) 4.5 (3.7) 
Controlled Word Association Test (FAS) 30.8 (12.0) 31.2 (17.0) 
Similarities 13.0 (6.2) 12.7 (5.8) 
Finger Tapping (dominant hand) 36.7 (11.8) 41.3 (10.8) 
Finger Tapping (non-dominant hand) 33.9 (9.2) 37.2 (8.8) 
Mini Mental State Examination, median (q1, q3) 27.5 (24, 29) 27 (23, 29) 
 
Note: Results above are mean scores (standard deviation) unless otherwise stated. For 
MMSE and Trails A and Trails B, medians were used due to skewed data; 25%ile (q1) 
and 75%ile (q3) quartile values are reported in lieu of standard deviations for these items. 
Higher scores indicate better performance, with the exception of Trails A and Trails B 
(longer time is indicative of worse performance). Summary measures are based on the 
non-missing neuropsychological measures on cases and their matched control 
participants. Numbers of participants (PD or control) are not the same in all measures.  
 
Discussion 




PD diagnosis, compared to individuals who did not develop PD over the same timeframe. 
The neurodegeneration seen in the brain in PD (Braak staging) that is potentially relevant 
to cognition begins in lower brainstem and proceeds over time to midbrain substantia 
nigra and then to higher-order cortical areas. In accordance with this pattern, we did not 
expect to see group differences on the MMSE, a generally non-specific metric of global 
cognitive functioning, or on tests of memory and executive functioning, as these 
cognitive domains are usually considered to require the integrity of cortical areas. We 
hypothesized that tests of attention and arousal, which are subserved by lower-brainstem 
as well as by higher-order regions, may have been sensitive to pre-diagnostic deficits, but 
this hypothesis was not supported.  
Our finding for the MMSE is consistent with those of Sánchez-Ferro and 
colleagues (2013) but is inconsistent with those of the Rotterdam report, in which subtle 
cognitive deficits were evident up to 7 years pre-diagnosis of PD, as well as reports from 
small prospective samples and at-risk population groups that have also noted an 
association between declining cognition and development of PD (Darweesh et al., 2017; 
Pausch et al., 2016; Chahine et al., 2016). Findings of cognitive deficits prior to PD 
diagnosis may depend on careful attention to the individual cognitive domains being 
assessed and the sensitivity of the measures used. 
Between 15-20% of individuals with de novo PD have been reported as meeting 
criteria for MCI using a variety of definitions (Aarsland, 2016). Cognition in early PD 
has been examined using a variety of assessment measures and definitions of impairment, 




examined in the Rotterdam study, with the exception of the MMSE. Although the MMSE 
is a commonly used measure for detecting dementia, it is generally insensitive to mild 
cognitive changes (Chou et al., 2010). The MoCA has been described as more sensitive 
to cognitive changes in PD due to the inclusion of executive features and more 
challenging visuospatial and memory items when compared to the MMSE (Aarsland 
2016; Papagno & Trojano, 2018). 
The Rotterdam trial reported that their tests under-represented attentional-
executive dysfunction and impaired visuoperceptual skills in PD; nevertheless, they 
reported significant differences. Our tasks that included more aspects of attention, 
executive functioning, and visual memory skills did not find case-control differences. 
Longitudinal samples are typically limited by the types of measures available for 
analysis, as most study protocols were originally designed with other outcome measures 
in mind. Although FHS uses a comprehensive neuropsychological assessment, our 
measures may likewise be insensitive to detecting early cognitive change in PD. 
Despite a large sample with many years of follow-up, as with other studies we 
were constrained by small sample sizes. Although PD is the second most common 
neurodegenerative disorder after Alzheimer’s disease, the incidence is still relatively low 
and extremely large samples and/or long follow-ups are necessary to identify a sample 
with enough power to detect significant differences. Our sample was older than what is 
traditionally seen for the pre-diagnostic phase of PD; effects of normal aging on 
cognition may have impacted our ability to identify robust differences in our groups. 




generation and developed PD prior to the initiation of regular cognitive assessment. 
Therefore, longitudinal study of cognitive change over time was not possible. Future 
research in these cohorts will provide valuable opportunities to examine for the presence 
of declining cognitive abilities, as well as potential conversion to dementia. 
Identifying biomarkers of PD will be critical to the ability to detect PD in its 
earliest stages before motor symptom onset. Such identification will require the use of 
prospective, longitudinal research. A strength of our study was the inclusion of study 
participants irrespective of traits that affect risk of PD. Although samples of high-risk 
populations may improve sample sizes of participants, community-based studies allow us 
to identify etiologic factors for PD from the general aging population, rather than just 
those who present with a characteristic that has high specificity for PD, but is rare in the 
overall population of individuals with PD. Studying individuals with only those 
characteristics may skew our understanding of disease development and progression.  
Because the search for biomarkers is consuming of time and resources, it is vital 
to capitalize on opportunities to analyze previously collected data in novel ways, 
including the use of epidemiological datasets that were developed with other health-
related aims. Identifying which suspected biomarkers do not provide useful information 
in detecting risk for PD is an important study outcome, as these results can inform the 










Neuropsychiatric symptoms including anxiety, depression, apathy, and 
hallucinations are some of the most common non-motor features reported by individuals 
with Parkinson’s disease (PD) (Szatmari et al., 2017). These symptoms are often under-
recognized and may go untreated due to poor understanding of mental health issues, 
limited detection abilities, poor access to care, and de-prioritization in comparison to 
other symptoms (Dobkin et al., 2013; Weintraub, Moberg, Duda, Katz, & Stern, 2003; 
Chaudhuri et al., 2009). Neuropsychiatric symptoms have a significant adverse impact on 
quality of life and contribute to caregiver burden and use of health resources (Weintraub, 
2013; Marsh & Berk, 2003; Global Parkinson’s Disease Steering Committee, 2002; 
Schrag, Jahanshahi, & Quinn, 2000; Findley et al., 2003). These symptoms have been 
reported to emerge in the early stages of clinical PD or in the pre-diagnostic period before 
the emergence of motor symptoms. Depression is among the more well-studied of these 
symptoms.  
A meta-analysis identified the combined prevalence of clinically significant 
depressive symptoms in PD to be 40-50% (Marsh 2013). Risk factors for depression in 
PD were recently summarized by Szatmari et al. (2017) and include female gender, 




motor disability, longer disease duration, right-sided disease dominance, akinetic-rigid 
disease subtype, restless leg syndrome, and higher daily doses of levodopa.  
Neuroimaging studies have attempted to reveal the pathological mechanisms 
underpinning the development of depression in PD. Neurodegeneration in the raphé 
nuclei and locus coeruleus at Braak stage 2 supports the observation that mood 
disturbance may be a pre-diagnostic symptom of PD. Relevant findings include decreased 
hippocampal and amygdala volumes (van Mierlo, Chung, Foncke, Berendse, & van den 
Heuvel, 2015; Surdhar et al., 2012) and increased metabolism in the amygdala (Huang et 
al., 2013), while there are conflicting findings regarding the integrity of limbic-prefrontal 
connections (van Mierlo et al., 2015; Sheng et al., 2014; Hu et al., 2015). There is also 
evidence of reduced volume in certain orbito-frontal and temporal regions (Feldmann et 
al., 2008; Kosti et al., 2010; Matsui et al., 2007).  
Depressed mood has long been described as a frequent presenting complaint 
(Barone et al., 2009; O’Sullivan et al., 2008) predating motor symptoms (Santamaria, 
Tolosa, & Valles, 1986). Several case-control studies and cohort studies have reported 
associations between PD and pre-diagnostic depression (Ishihara & Brayne, 2006; 
Leentjens, Van den Akker, Metsemakers, Lousberg, & Verhey 2003; Alonso, Rodríguez, 
Logroscino, & Hernán, 2009), though not all (see Bower et al., 2010). Some of the more 
recent research has shown an increased risk of PD in those with depression spanning a 
follow-up period of more than 2 decades (Gustafsson, Nordström, & Nordström, 2015). 
Prevalence rates of premorbid depressed mood have been reported to be between 23 and 




warranting inclusion in the MDS research criteria for pre-diagnostic PD (Berg et al., 
2015). A likelihood ratio of 1.8 was defined based on the evidence reported in five large 
population-based studies, indicating an increased risk of PD attributed to presence of 
depression by just under 15% (Schrag, Horsfall, Walters, Noyce, & Petersen, 2015; 
Leentjens, Van den Akker, Metsemakers, Lousberg, & Verhey 2003; Alonso, Rodríguez, 
Logroscino, & Hernán, 2009; Fang et al., 2010; Gustafsson, Nordström, & Nordström, 
2015).  
Research quality has been affected by symptom overlap between pre-diagnostic 
depression in PD and major depression without PD, including fatigue, psychomotor 
slowing, apathy, and impairments in sleep, memory, and concentration (Postuma et al., 
2012). PD-related depression has been described as milder, but more frequently 
involving symptoms of apathy and anhedonia than depression in individuals without 
PD (Schapira, Chadhauri, & Jenner, 2017). PD-specific questionnaires may be needed 
in order to capture depression as an independent risk factor for PD. There is also the 
possibility that depression may manifest as a mood reaction to PD diagnosis and 
symptom progression, complicating our attempts to understand its etiology (Szatmari et 
al., 2017). 
Population-based studies, including those in the evidence base used by the MDS 
in creating specific research criteria for pre-diagnostic PD, have all counted depression 
using data from electronic health records, such as codes for the diagnosis of depression or 
the use of antidepressant medication. Some studies have looked at self-reported mood, 




symptoms including anhedonia, apathy, and a general “mood disturbance” item in 
individuals who developed PD compared to those who did not (Pont-Sunyer et al., 2015). 
Self-report scales of PD are less well studied and their utility for identifying risk of 
clinically significant PD in the pre-diagnostic phase is unclear. One recent study reported 
differences in scores between individuals who developed PD and those who did not on 
the Center for Epidemiologic Studies Depression Scale (CES-D) questionnaire that 
became significant approximately 2.3 years pre-diagnosis. 
Anxiety and apathy have also been reported in pre-diagnostic PD (Bower et al., 
2010; Winkler et al., 2011). Three population-based studies examining anxiety as a risk 
factor were evaluated in determining the MDS research criteria described earlier for pre-
diagnostic PD, with lower likelihood ratios than those seen for depression (Schrag, 
Horsfall, Walters, Noyce, Petersen, 2015; Weisskopf, Chen, Schwarzschild, Kawachi, & 
Ascherio, 2003; Bower et al., 2010). Isolated anxiety without comorbid depression was 
not added to the criteria for calculating pre-diagnostic PD at the time of the task force 
report, though researchers were instructed to consider its impact on risk given the high 
comorbidity between anxiety and depression (Berg et al., 2015). Recent reports have 
documented significant apathy in newly diagnosed PD (Dujardin et al., 2014; Santangelo 
et al., 2015) and in individuals prior to onset of motor symptoms (Pont-Sunyer et al., 
2015). Much additional work remains to be done to improve understanding of the 








This project examined data collected from individuals included in the first two 
generations of the Framingham Heart Study (FHS). As previously described, first 
generation (Gen 1) participants in FHS have undergone regular clinical examinations 
approximately every two years since 1948 and second generation (Gen 2) participants 
have undergone exams approximately every four years since 1971. Protocols are in place 
for surveillance for the development of a number of medical conditions. PD is assessed 
through regular consensus meetings, and the review process includes careful assessment 
of all FHS clinical examinations and outside medical records by a team including at least 
one neurologist to determine whether individuals flagged for potential PD meet UK Brain 
Bank criteria for diagnosis (Hughes et al., 1992).  
The final study sample included 32 individuals diagnosed with PD who had 
completed the CES-D between one and five years prior to diagnosis. The large size of the 
overall FHS sample made it possible to identify seven control participants matched to 
each participant with PD, which maximized statistical power. The 224 control 
participants were matched to the PD group based on age, sex, and education. 







Table 4. Demographic characteristics of PD cases and matched control sample for depression analyses. 




Mean age, years (SD) 76.9 (9.2) 76.9 (9.3) 
Men, n (%) 18 (56%) 126 (56%) 
Education, n (%) 
















The CES-D questionnaire is a 20-item scale that asks individuals to rate how 
often they have felt symptoms over the previous week: rarely or none of the time (less 
than one day per week), some or a little of the time (1-2 days per week), occasionally or a 
moderate amount of time (3-4 days per week), and most or all of the time (5-7 days per 
week). The symptoms comprise four factors: depressive affect, somatic complaints, 
positive affect, and interpersonal relations. While most items are negatively worded (e.g. 
“I was bothered by things that usually don’t bother me”), four items are interspersed with 
positive wording (e.g. “I felt hopeful about the future”) and are reverse scored. Total 
scores range from 0 to 60; higher scores reflect more depressive symptoms. Guidelines 
have recommended a cut-off score of 16 to indicate depression (Radloff, 1977).  
 
Data Analysis  
PD cases were compared to control participants matched for age, sex, and 
education level. Average CES-D total score was used as a continuous variable. A p-value 







A total of 32 individuals in the FHS sample completed the CES-D between one 
and five years pre-diagnosis of PD. Mean age at testing for those with PD was 76.9 years 
(SD = 9.2). Mean age at testing for control participants was 76.9 years (SD = 9.3). Males 
made up 56% of each group. Depression scores were not significantly different for men 
and women and did not significantly differ by education level. Additionally, depression 
scores were not significantly correlated with age. Table 5 summarizes mean depression 
scores for PD cases and the control group. 
Mean score on the CES-D was 6.66 (SD = 8.28) for individuals who went on to 
develop PD and 6.37 (SD = 7.79) for those who did not. We were underpowered to 
consider significant differences between groups using a cut-off score for clinical 
depression. Only three members of the PD group met criteria for depression using a cut-
off score of 16 (9.4%), while 26 members of the control group met criteria using this cut-
off (11.6%). 
There were no significant differences found between control participants and PD 
cases for total CES-D score (p=0.85). Table 5 summarizes CES-D scores for PD cases 






Table 5. Comparison of scores for depression measure in cases (1-5 years before PD diagnosis) and control 
group. 
 PD cases  Control group 




Figure 1. Distribution of total depression scores by group. 
 
Discussion 
A self-report questionnaire did not indicate differences in level of depression for 
individuals prior to PD diagnosis, compared to individuals who did not develop PD over 




conversion to PD in several population-based studies (Schrag, Horsfall, Walters, Noyce, 
& Petersen, 2015; Leentjens, Van den Akker, Metsemakers, Lousberg, & Verhey 2003; 
Alonso, Rodríguez, Logroscino, & Hernán, 2009; Fang et al., 2010; Gustafsson, 
Nordström, & Nordström, 2015). A limitation of each of these studies was that they 
based depression diagnosis on medical record coding methods. Specifically, individuals 
with medical record codes for diagnosis of clinical depression or use of psychotropic 
medications were found to have a higher risk of future conversion to PD than those who 
did not. Fewer studies have examined self-reported depressive symptoms, which may or 
may not be representative of clinical depression. 
 The Rotterdam study used the CES-D questionnaire to track depressive symptoms 
prior to conversion to PD in a sample of 109 PD participants with 10 matched control 
participants for each (total n = 1199) (Darweesh et al., 2017). They reported that 
depressive symptoms were more common for PD converters up to 15 years before 
diagnosis, but the group difference was not significant until 2.3 years pre-diagnosis. Of 
note, average CES-D scores for both PD and control participants fell below the generally 
accepted cut-off of 16 to indicate clinically significant depression (Radloff, 1977). 
Although specific values were not published, graphical representation of scores over time 
indicated that average scores varied between groups by fewer than 3 points, and scores 
for the PD group were more variable than those in the control group over the follow-up 
period.  
 The time to conversion using clinical depression as a risk factor has been reported 




pre-diagnosis (Fang et al., 2010; Gustafsson, Nordström, & Nordström, 2015), while 
others did not find differences until 2-3 year before disease onset (Leentjens, Van den 
Akker, Metsemakers, Lousberg, & Verhey 2003; Alonso, Rodríguez, Logroscino, & 
Hernán, 2009). Some have suggested that there may be a bimodal relation between 
depression and PD in which individuals with longstanding dysthymia or anxiety are at 
increased risk for PD (see Ishihara & Braine, 2006 for a review of parkinsonian 
personality), while others experience mood disruption as a result of pathological changes 
occurring as the pre-diagnostic stage moves toward the clinical disease phase (Postuma & 
Berg, 2016). 
Despite having access to the large FHS sample with two generations of 
participants to consider, like other studies we were constrained by small sample sizes. 
Although FHS began in 1948, the CES-D was not added to the core clinical exam until 
1995. Therefore, we did not have CES-D data available for all participants who converted 
to PD and were working with a shorter follow-up period than that available to the 
Rotterdam trial. 
Additionally, very few of our PD cases met criteria for clinically significant 
depression using recommended cut-offs for the CES-D questionnaire. Depression in PD 
has been reported to be milder than in the general population with depression, with more 
frequent complaints of apathy and anhedonia in PD (Schapira, Chadhauri, & Jenner, 
2017). Only total scores for the CES-D questionnaire were available for this analysis. 
Future research should examine for differences in the four identified factors of the 




relations) or specific questionnaire items. A recent review of depression rating scales in 
PD recommends the Hamilton Rating Scale for Depression or the self-report Geriatric 
Depression Scale as having the best evidence base for use in this population (Torbey, 
Pachana, & Dissanayaka, 2015). The contribution and potential overlap of other mood 
disorders, such as anxiety and apathy, also warrant further examination in PD. 
Self-report questionnaires used to screen for depressive symptoms are 
inexpensive in both time and monetary resources, suggesting that they may be obvious 
and valuable additions to assessment of PD risk. Reducing enthusiasm for their inclusion 
are questions regarding the reliability of self-reported depressive symptoms to identify 
risk of PD conversion, and the timing and severity of symptoms necessary to reach this 
threshold. It remains unclear if depression in PD arises directly from disease pathology, 
as a reaction to subsequent disability, or coincidentally with but not directly related to 
PD; there is likely room for all of these explanations in this heterogeneous disorder 
(Schapira, Chaudhuri, & Jenner, 2017). Depressive symptoms do not reliably respond to 
dopaminergic therapy in PD, consistent with other non-motor symptoms that may go 
untreated despite having significantly negative impacts on quality of life (Schapira, 
Chaudhuri, & Jenner, 2017). Reliable identification of depressive symptoms is relevant 
not only for understanding risk of conversion to PD, but also to ensure timely and 











An unbiased biomarker-driven subtyping of Parkinson’s disease (PD) may allow 
for a better ability to address questions about the early stages of PD than a clinical 
phenotype-driven subtyping. In recent years, research has flourished examining risk 
factors derived from genetic analysis, structural and functional neuroimaging, 
biochemical and molecular biomarkers, markers of oxidative stress, and the “-omics” 
approaches (e.g. transcriptomics, proteomics, and metabolomics) (Espay et al., 2017). 
This work has identified a number of promising candidates, but few have reached the 
threshold for inclusion in the Movement Disorder Society research criteria for pre-
diagnostic PD.  
The inflammatory hypothesis states that microglia-activated neuroinflammation 
may explain progressive nigrostriatal neurodegeneration in PD (Lee, Tran, & Tran, 
2009). Early work identified elevated levels of certain inflammatory cytokines in 
cerebrospinal fluid and plasma in post-mortem and clinical human studies of PD 
(Nagatsu & Sawada, 2005; Dobbs et al., 1999; Dufek et al., 2009). A recent examination 
of immune-inflammatory and oxidative stress pathways found elevated levels of soluble 
transferrin receptor, haptoglobin, interleukin-6 (IL-6), malondialdehyde ferritin, and 
reduced levels of transferrin in individuals with PD when compared with control 




interleukin-12 (IL-12) have also been demonstrated in individuals with PD in comparison 
to control adults without PD (Rentzos et al., 2009). The relation of plasma markers of 
inflammation to disease progression has also been studied. PD participants with higher 
levels of C-reactive protein (CRP) at baseline have been found to have significantly 
greater deterioration in motor functioning over a 2.5-year follow-up (Umemura et al., 
2015). Additionally, baseline levels of serum IL-6 were found to be higher for PD 
participants who died than those who survived a four-year follow-up period (Dufek, 
Rektorova, Thon, Lokaj, & Rekotr, 2015).  
Few studies have aimed to examine how soon neuroinflammation may be 
identified, and if it could be a potential biomarker for pre-diagnostic PD (Chen, O’Reilly, 
Schwarzschild, Ascherio, 2008). Reduced plasma levels of urate may be related to 
reduced risk of PD development (Noyce et al., 2012). Increased levels of IL-6 were found 
to be associated with greater risk of PD in the Health Professionals Follow-up Study, 
with no increased risk identified for CRP, fibrinogen, and tumor necrosis factor alpha 
(TNF-α) receptors (Chen, O’Reilly, Schwarzschild, Ascherio, 2008). One study of 
incident PD among Japanese-American men reported a significant association between 
high fibrinogen levels and PD risk (Wong et al., 2009). The Cardiovascular Health Study 
Cohort showed an increased prevalence of PD in women with high IL-6 levels and in 
men with high white blood cell count, but incident PD was not associated with any 
examined biomarkers (Ton et al., 2012). These mixed results necessitate further research 




no plasma marker has reached sufficient sensitivity or specificity to be considered to be a 
diagnostic marker of PD (Postuma et al., 2015).  
Understanding more about inflammatory markers in PD may also provide insight 
into other non-motor symptoms in PD. Inflammation has been proposed as a contributor 
to the development of both cognitive impairment and depression in older adults (Gorelick 
2010; Dowlati et al., 2010). Depression has also been implicated as a risk factor for 
cognitive decline in older adults (Ownby et al., 2010). More recent research has found 
that the relation between depressive symptoms and cognitive decline with age may be 
mediated by increased inflammation (Gallagher, Kiss, Lanctot, & Herrmann, 2016). 
Much recent research has focused on the interactions between cognition and mood states 
in PD. For example, anxiety has been shown to be related to cognitive dysfunction in this 
disorder (Reynolds et al., 2017).  
As depression and cognitive dysfunction are both prominent non-motor symptoms 
of PD, researchers have begun to explore how inflammatory markers and these symptoms 
work individually and together in this disorder, though varying methodologies have 
contributed to disparate results. One group found that plasma levels of soluble 
interleukin-2 receptor and TNF-α were significantly associated with more severe 
symptoms of fatigue, depression, and anxiety (Lindqvist et al., 2013). Another team 
demonstrated that individuals with higher IL-levels had significantly lower scores on the 
Mini Mental State Examination (MMSE) (Scalzo, Kümmer, Cardoso, & Teixeira, 2010). 
Rocha and colleagues (2014) reported that higher levels of soluble tumor necrosis factor 




correlated with poorer cognitive test scores, as measured by the Frontal Assessment 
Battery (FAB). MMSE score was negatively correlated with sTNFR1, but not with 
sTNFR2. sTNFR1 (but not sTNFR2 or Beck Depression Inventory scores) was shown to 
be a significant predictor of FAB scores. Menza and colleagues (2010) reported that 
plasma level of TNF-α (but not IL-1beta, IL-6, IL-10, or cortisol) was significantly 
correlated with cognition, depression, and self-reported disability in relation to activities 
of daily living in PD.  
Although some research has begun to explore the relation between inflammation 
and cognitive dysfunction and depression in those with PD, less is known about whether 
either of these factors contribute to the development of diagnosed PD dementia. The 
point prevalence (percent of those sampled at a specific point in time) of dementia in PD 
is close to 30%, but at least 75% of those surviving at least 10 years may go on to 
develop dementia (Aarsland & Kurz, 2010). Disease severity, age, presence of PD-Mild 
Cognitive Impairment, psychiatric features (such as visual hallucinations), and genetic 
factors have all been implicated in contributing to dementia risk in PD, but reliable 
biomarkers for dementia in PD have not been identified (Aarsland & Kurz, 2010). 
Surprisingly, researchers have not yet determined whether high levels of inflammatory 
markers increase PD dementia risk, though this was reported years ago for Alzheimer’s 
disease (Tan et al., 2007). Depression has been shown to increase risk for dementia in 
healthy adults (Saczynski et al., 2010), and individuals diagnosed with depression 
following a diagnosis of PD have recently been reported to have higher risk for 




Work from the previous two studies of this project (described in Chapters 2 and 3) 
did not find evidence for the role of impaired cognition and self-reported depression as 
pre-diagnostic risk factors of Parkinson’s disease. Additional work remains to be done to 





This project examined data collected from individuals included in the second 
generation of the Framingham Heart Study (FHS). As previously described, the second 
generation of participants in FHS (total n=5,124) were enrolled in 1971 and have 
undergone regular clinical examinations approximately every four years since that time, 
along with surveillance for the development of a number of medical conditions. Cases of 
PD are identified during regular consensus meetings, during which FHS clinical 
examinations and outside medical records are examined by a team including at least one 
neurologist to determine whether individuals suspected for potential PD meet UK Brain 
Bank criteria for diagnosis (Hughes et al., 1992).  
The final sample included 19 individuals with plasma CRP levels measured 
between 1-5 years prior to diagnosis of PD. The large size of the overall FHS sample 
made it possible to identify eight healthy control participants matched to each participant 
with PD, which maximized statistical power. The 152 control participants were matched 




significant differences reported between groups on these factors. Detailed demographic 
information is reported in Table 6. 
 
Table 6. Demographic characteristics of PD cases and matched control sample for primary inflammatory 
marker analyses. 
 PD Cases  
(n=19) 
Control Group  
(n=152) 
Age, years (SD) 69.4 (10.7) 69.4 (10.4) 
Men, n (%) 12 (63%) 96 (63%) 
Education, n (%)* 















Seven participants also had three additional plasma levels of inflammation 
available for analysis that were collected pre-diagnosis of PD. Each of these seven 
individuals was able to be matched to four control participants. A total of 28 control 
participants were included in the sample, matched for age, sex, and education. Detailed 
demographic information for this subset is reported in Table 7. 
 
Table 7. Demographic characteristics of PD cases and matched control sample for subset inflammatory marker 
analyses. 
 PD Cases  
(n=7) 
Control Group  
(n=28) 
Age, years (SD) 67.0 (9.0) 67.1 (8.6) 
Men, n (%) 5 (71%) 20 (71%) 
Education, n (%)* 



















Plasma markers available for analysis included CRP, IL-6, interleukin-18 (IL-18), 
and TNF-α. Fasting morning samples were collected and plasma and serum aliquots were 
stored at −70°C. Additional details regarding plasma sample collection and analysis have 
been published (Jefferson et al., 2011; Kathiresan et al., 2006). 
 
Data Analysis  
PD cases were compared to matched control participants for each inflammatory 
marker. Comparisons between inflammatory marker levels and demographic factors were 
also considered for the total group. A p-value of <0.05 was considered to be significant. 
Non-parametric analyses were used to examine the data from the subset of participants 
with additional inflammatory marker data due to small sample sizes. Because some 
skewing was observed in the inflammatory marker values, a natural log transformation of 
the data was conducted, which did not change the results of the analyses. Results from 




CRP levels were not significantly different for individuals with PD and control 
participants. There was no significant correlation between CRP level and either sex or 
education level for the total sample. There was a significant positive correlation between 




Table 8 and Figure 2. 
 
Table 8. Comparison of C-reactive protein levels for cases (1-5 years before PD diagnosis) and control group. 








Figure 2. Correlation between age and C-reactive protein levels for total sample. 
 
No significant differences were found for IL-18, IL-6, or TNF-α between 




between sex or education level and any inflammatory marker level for the total sample. 
TNF-α was significantly positively correlated with age for the total sample (p = 0.0017). 
These results are summarized in Table 9 and Figure 3. 
 
Table 9. Comparison of subset inflammatory marker levels for cases (1-5 years before PD diagnosis) and control 
group. 




IL-18 (pg/ml) 255.88 (63.77) 246.05 (86.96) 
IL-6 (pg/ml) 2.49 (1.47) 3.44 (4.80) 
TNF-α (pg/ml) 2688.66 (1140.62) 3054.05 (1373.67) 
 
 





Levels of plasma inflammation did not indicate differences between individuals 
prior to PD diagnosis and individuals who did not develop PD over the same timeframe. 
The Health Professionals Follow-up Study (Chen, O’Reilly, Schwarzschild, Ascherio, 
2008) found that PD participants with higher baseline levels of IL-6 had increased risk 
for development of PD over study follow-up, which is inconsistent with the findings of 
the present study. Neither study found a significant relation between CRP and TNF-α in 
those who went on to develop PD. Higher baseline levels of IL-6 and CRP were not 
found to increase risk for PD development in the Cardiovascular Health Study Cohort 
study, which is consistent with our results (Ton et al., 2012). 
Immunosenescence is a term used to define the age-related decline in immune 
function that has been reported in elderly populations (Acardi & Caruso, 2018). This is a 
complex process that includes changes that can be seen on a cellular level and in serum 
biomarkers. Many inflammatory markers have been shown to increase with age, even if 
they remain within normal clinical limits (Czarkowska-Paczek, Zielenkiewicz, & Paczek, 
2016). In our sample, increasing age was significantly correlated with levels of both CRP 
and TNF-α. This correlation was not significant for IL-6 and IL-18. In our study and in 
other published work (e.g., Ton et al., 2012; Chen, O’Reilly, Schwarzschild, Ascherio, 
2008), results included large standard deviations, indicative of large individual 
differences. More work remains to be done to determine the effects of aging on 




This study was limited to examining a small set of potential biomarkers available 
from the FHS dataset, and they may not have been ideal candidates to investigate PD 
specifically. Multiple biomarkers were available for only a small subset of individuals, 
and additional biomarkers of interest were not available at all, including urate and 
fibrinogen. Examining existing blood samples in the FHS that have yet to be completely 
processed may offer the opportunity to develop a more comprehensive picture of the 
relation between plasma inflammation and PD risk. 
Levels of inflammation and performance on measures of neuropsychological 
functioning have been studied in the FHS by Jefferson and colleagues (2011), using the 
markers examined here as well as others. These investigators reported that individuals 
with higher CRP levels showed significantly worse performance on a measure of visual 
organization and that those with higher TNF-α levels had worse reading performance 
demonstrated cross-sectionally, as well as steeper decline in performance on an executive 
functioning measure demonstrated longitudinally. Examining how levels of inflammation 
may impact cognitive functioning in PD specifically, as well as how inflammation may 
interact with mood symptoms such as depression, will be useful for developing a better 
understanding of the contribution of inflammation to PD risk and progression. Although 
the studies described in this and previous chapters did not find evidence of impaired 
cognition, self-reported depression, or increased inflammation in the pre-diagnostic 
period, additional work exploring the relation of these three markers to each other on a 




Levels of inflammation vary significantly over time, and the pre-diagnostic phase 
in PD has grown longer with newly identified markers of risk. Cohort studies may not 
fully capture changes occurring in the inflammatory process in PD. Longitudinal samples 
with repeated measures of a comprehensive assessment of inflammation will be essential 





CHAPTER FIVE: GENERAL DISCUSSION 
 
Parkinson’s disease (PD) is now known to be preceded by a pre-diagnostic phase 
of many years. Markers of this phase have been proposed that may predict conversion to 
the diagnosed disease, including subtle motor dysfunction (e.g. reduced hand motor 
speed; different from the cardinal motor signs of the diagnosed disease), abnormalities 
detected through imaging techniques, and fluid and tissue biomarkers. Some of the most 
promising of these markers relate to the non-motor symptoms of PD, including sensory, 
sleep, and autonomic dysfunction, mood disturbance, and cognitive impairment 
(Schapira, Chaudhuri, & Jenner, 2017). In order to intervene in early stages of disease 
with neuroprotective therapies, we must develop a better understanding of this pre-
diagnostic period. This dissertation project contributed to this effort by investigating three 
potential pre-diagnostic markers of PD: cognitive functioning (Study 1), depression as a 
marker of mood disturbance (Study 2), and plasma biomarkers of inflammation (Study 
3).  
Study 1 investigated the presence of cognitive dysfunction pre-diagnosis of PD 
using a global screening measure (Mini-Mental State Examination, MMSE) and more 
comprehensive neuropsychological assessment, comparing the performance of identified 
PD cases and matched control participants. The Braak staging model for 
neurodegeneration in PD has demonstrated that pathology spreads from brainstem to 
midbrain to cortical regions (Braak et al., 2003; Braak, Ghebremedhin, Rüb, Bratzke, & 




cognitive changes in PD may occur in tasks affected by attention and arousal. The 
hypothesis was that individuals who went on to develop PD would not be impaired on the 
MMSE or on tests of higher-order learning and memory, but would possibly show 
impaired performance on tests that examined attentional resources, such as Digit Span 
and the Trail Making Test. Consistent with the prediction, there was no significant 
difference in scores on the MMSE for individuals 1-3 years pre-diagnosis of PD 
compared to control participants matched for age, sex, education, and a number of 
identified risk factors for cognitive impairment. No significant differences were found 
between groups for any of the more comprehensive neuropsychological assessments that 
included tasks of attention, working memory, executive functions, verbal and non-verbal 
memory, abstract reasoning, and motor functioning, meaning that the hypothesis that 
attention might be affected was not supported.  
The finding with the MMSE is consistent with that of Sánchez-Ferro and 
colleagues (2013), who reported no significant differences in rate of decline in MMSE 
scores for individuals with pre-motor PD over a three-year follow-up period. Of note, 
their version of the MMSE included three additional items: an attention task, a command, 
and a simple visuoconstruction task. The results of the present study are inconsistent with 
those of the Rotterdam report, in which differences in MMSE scores between those who 
would convert to PD and those who would not diverged 5.6 years pre-diagnosis 
(Darweesh et al., 2017). The Rotterdam study also found cognitive deficits up to 7 years 
pre-diagnosis, beginning with the domains of processing speed and executive function, 




larger and the protocol included a more comprehensive clinical assessment of PD 
including motor staging using the Unified Parkinson’s Disease Rating Scale. An 
advantage of their study was that they were able to assess the trajectory of potential 
markers of PD across multiple time points. Despite these promising results, the cognitive 
assessments that they used under-represented the domains most salient to PD, including 
visuospatial and attentional-executive skills. The use of objective cognitive measures to 
predict PD development will require additional study. 
Mood disturbances are highly prevalent and relatively under-recognized and 
undertreated non-motor symptoms of PD that have significant negative impact on quality 
of life (Szatmarti et al., 2017). While apathy, anxiety, and other psychiatric features such 
as delusions and hallucinations have been examined in PD, depression remains the most 
well studied. Study 2 examined self-reported depression as a pre-diagnostic marker for 
PD. The hypothesis was that individuals who went on to develop PD would have higher 
scores on the Center for Epidemiologic Studies Depression Scale (CES-D) than those 
who did not convert to PD. 
There were no significant differences in scores between cases and a matched 
control group 1-5 years pre-diagnosis of PD. Most previous research that has 
demonstrated depression to be an important predictor of PD have relied on the presence 
of clinically diagnosed depression as identified through medical record coding systems, 
rather than through self-report. Our findings are inconsistent with those of the recent 
Rotterdam trial, which found differences on the CES-D questionnaire between 




years pre-diagnosis (Darweesh et al., 2017). Of note, in the samples of both the 
Rotterdam and present studies, average CES-D scores were below the recommended 
clinical cut-off for depression. The low number of cases meeting clinical criteria for 
depression was too small to allow for analysis of rates of depression between groups in 
the current project. While appealing from a resource perspective because it is quick and 
inexpensive to administer a questionnaire, self-reported depression may not be as relevant 
as a clinical diagnosis of depression in the years leading up to a PD diagnosis. 
Study 3 examined available biomarkers of plasma inflammation, as 
neuroinflammation has been suspected to play a role in neurodegeneration in PD. The 
hypothesis was that levels of plasma biomarkers of inflammation would be significantly 
higher for individuals pre-diagnosis of PD than for the control group. There were no 
significant group differences for the primary outcome, C-reactive protein (CRP) levels, 
nor for the analysis in which the PD group was a smaller subset for whom additional data 
were available on interleukin-18 (IL-18), interleukin-6 (IL-6), and tumor necrosis factor 
alpha (TNF-α). Chen and colleagues reported higher levels of IL-6 related to increased 
PD risk (inconsistent with the findings reported here), but no significant increased risk 
from elevated levels of other plasma measures of inflammation including CRP 
(consistent with the present findings). Ton and colleagues (2012) also did not find 
increased risk of PD for those with elevated IL-6 levels. In the present sample, there were 
significant positive correlations between age and both CRP and TNF-α, consistent with a 
recent study reporting this finding for a number of plasma inflammatory markers 




levels of plasma inflammation in clinically diagnosed PD, the role of inflammation 
during the pre-diagnostic period will require more study. 
 
Benefits and Challenges of Epidemiological Study 
This project benefitted from the use of the Framingham Heart Study’s (FHS) 
longitudinal follow-up of multiple generations of participants. The contribution of the 
FHS to our understanding of cardiovascular disease is perhaps unmatched (Wong, Levy, 
and Narula, 2013). While FHS continues to provide new insights in this area, the use of 
its data for investigation of disease outside the heart may be its more enduring legacy. 
Longitudinal research remains the gold standard for identifying risk factors of disease due 
to the prospective nature of the data; however, it is expensive in both time and resources. 
Therefore, the opportunity to capitalize on previously collected datasets should not be 
missed. 
Despite the obvious benefits of working with previously collected data, there are a 
number of challenges that accompany this work. Most importantly, this research is 
limited by the protocol that was designed with other outcomes in mind, meaning that the 
data available may or may not represent best practices for studies in additional diseases. 
As FHS moves to consider aging processes, it is fortunate, from a research standpoint, 
that what has been found to be detrimental to cardiovascular functioning also has 
negative impacts on the brain. Hence, much of the data collected is relevant to the study 
of neurodegenerative disease and associated cognitive decline. For specific disease states 




that regularly examine this disorder, such as results of PD-specific questionnaires (e.g., 
Parkinson’s Disease Questionnaire-39, a quality of life measure) and details about the 
appearance and nature of symptoms (e.g., side of onset and initial symptom). 
Also missing from our investigation of PD was comprehensive assessment of 
motor functioning (e.g. Unified Parkinson’s Disease Rating Scale, UPDRS). This 
assessment would have allowed a more confident confirmation of disease diagnosis, 
earlier in the disease course, without the need to wait for outside medical record 
confirmation. An additional limitation was that although the FHS is a longitudinal 
project, PD symptoms are recorded at time of case ascertainment. While progression of 
certain symptoms may be inferred through their inclusion in repeated clinical exams (e.g., 
mood questionnaire), no data were available to systematically document the relevant 
clinical features of PD as the disease progresses. A self-report questionnaire was used to 
identify depression in this project, but no information was available for this project that 
would allow the identification of FHS participants who would have met criteria for a 
clinical diagnosis of depression, or that could control for the impact of psychotropic 
medications. For example, individuals prescribed antidepressants may have low CES-D 
scores due to treatment effects.  
The incidence rate of PD is low. Even in a multi-generational sample of over 
10,000, it took nearly seven decades to identify just over 150 individuals for study. 
Therefore, a number of these individuals were diagnosed many years ago. The 
progression of technology, including electronic medical records, has led to more 




diagnostic sample identified in the FHS was considerably older than what is typically 
reported for development of PD in the general population, which may have been a 
consequence of the very strict criteria applied to identify and confirm cases using medical 
record review. Although comprehensive medical records were requested from 
participants, oftentimes it was unclear if the records that were received accurately 
documented the onset of the disorder, particularly the oldest records pertaining to this 
study sample. It is possible that this protocol overestimated disease diagnosis dates and 
included individuals who had been experiencing symptoms longer than what was 
documented. Diagnosis dates could be artificially inflated if participants did not seek 
timely treatment for their condition or there was confusion about the diagnosis, a state 
made more likely in the FHS sample by the lack of PD-specific measures such as the 
UPDRS. 
Another issue is that diagnostic criteria for diseases shift over the decades, 
requiring reinterpretation of old medical records to confirm case ascertainment. 
Identification of PD was formally updated in the FHS sample with the introduction of the 
UK Parkinson’s Disease Brain Bank Clinical Diagnostic Criteria (Hughes, Daniel, 
Kilford, & Lees, 1992). Recent work from the Movement Disorder Society has proposed 
additional changes in the diagnostic criteria for PD (Berg et al., 2014). Currently, 
presence of dementia precludes diagnosis of PD and points instead to Dementia with 
Lewy Bodies. Recent evidence has challenged this distinction, leading some to consider 




this diagnostic shift to the FHS sample may have implications for the potential validity of 
the pre-diagnostic markers assessed in this project.  
Advances in technology also have an impact on research methods, and the 
challenge in the FHS is to preserve the integrity of longitudinal data while adopting new 
approaches that have been identified as promising for new discovery. One area of focus 
in the FHS is the integration of technology into the assessment of cognitive functioning 
(Au, Piers, & Devine, 2017). In recent years, the FHS has incorporated the use of digital 
pen technology, first in the administration of the Clock Drawing Test, and later for all 
tasks requiring the participant to draw. Additionally, although originally collected for 
scoring and quality control purposes, thousands of digital voice recordings of 
neuropsychological assessments have been collected that can be available for vocal 
analysis. Technology may provide more sensitive metrics of neuropsychological 
functioning that may be particularly relevant to the analyses of cognition in this 
dissertation project. While enough digital pen data have not yet been collected for use in 
lower-incidence disorders such as PD, the state of these data is rapidly changing and 
digital voice analysis is currently ongoing. 
 Finally, work with long-standing datasets may necessitate dealing with 
complications related to data analysis and data sharing. Within the FHS database, there 
are literally millions of data-points available to explore and there is a steep learning curve 
to understanding how the data are organized and can be manipulated. FHS could benefit 
from better organization to capitalize on the resources that are available. For FHS, the 




complicate data sharing and collaboration. This issue is important because data sharing 
has been described as essential for progress in identifying biomarkers of PD (Frasier, 
2016). Additionally, machine-learning techniques may be better suited than traditional 
biostatistics methods to synthesizing this type of complicated data and developing a 
comprehensive profile of PD risk. 
 
The Future of Defining Pre-Diagnostic PD 
A number of highly promising pre-diagnostic markers of the development of PD 
were not examined in the current project, many of which represent the non-motor 
symptoms of the disease, as summarized in a recent review by Schapira, Chaudhuri, & 
Jenner (2017). Many of these markers are interrelated, with effects in one being found to 
impact other symptoms. Early neurodegeneration in the olfactory bulb leads to hyposmia, 
one of the most well-studied pre-diagnostic features of PD. Other sensory features such 
as visual disturbances have also been reported (reviewed in Putcha, Jaywant, & Cronin-
Golomb, 2016). Autonomic problems including constipation, orthostatic hypotension, 
and dysfunction in urinary and gastrointestinal systems are common and may support a 
more comprehensive hypothesis regarding the neuropathology in PD, in which alpha-
synuclein pathology spreads from the gut in a prion-like fashion (Braak et al., 2007; 
Schapira, Chaudhuri, & Jenner, 2017). Individuals with PD and orthostatic hypotension 
were recently found to have transient, posture-mediated decline in performance on 
cognitive measures that went beyond those seen in individuals with PD without 




Sleep disturbance is another critical feature to consider in pre-diagnostic PD. 
While Rapid Eye Movement Sleep Behavior Disorder (RBD) affects up to 24% of 
individuals with diagnosed PD (Zhang, Xu, & Liu, 2017), it is strongly predictive of later 
conversion to PD or related disorders, with up to 80% of individuals with this diagnosis 
eventually developing synucleinopathies (Peever, Luppi, & Montplaiser, 2014). In 
addition to RBD, individuals with PD may experience daytime somnolence, sudden-onset 
sleep attacks, periodic limb movements, restless leg syndrome, and insomnia (Schapira, 
Chaudhuri, & Jenner, 2017), as well as circadian rhythm dysfunction (Videnovic & 
Willis, 2016). Sleep has been related to cognitive impairment in those with PD 
(Stavitsky, Neargarder, Bogdanova, McNamara, & Cronin-Golomb, 2012) and more 
recently, the contribution of circadian dysfunction has been described as well (Wu et al., 
2018, submitted). Worse sleep quality has also been correlated with worse symptoms of 
anxiety and depression in PD (Junho, Kummer, Cardoso, Texeira, & Rocha, 2017). 
Improvements in functional imaging techniques have led to considerable research 
attempting to identify neuroimaging biomarkers of PD. A comprehensive recent review 
by Saeed and colleagues (2017) reported on recent evidence from structural magnetic 
resonance imaging (MRI) scans, diffusion tensor magnetic resonance imaging scans, 
dopaminergic positron emission tomography (PET) and fluorodeoxyglucose PET scans, 
presynaptic dopamine transporter imaging, single photo emission computed tomography 
(SPECT) scans, as well as amyloid and tau imaging and transcranial sonography. 
Abnormal PET/SPECT scans have been found to increase risk of PD conversion by more 




While alpha-synuclein in cerebrospinal fluid is the most well-studied molecular 
biomarker in PD, other markers are also of interest (as reviewed in Halbgebauer, Öckl, 
Wirth, Stenacker, & Otto, 2016). Redenšek, Dolžan, & Kunej (2018), have described 
recent findings using proliferating “-omics” approaches, or unbiased examinations of 
patterns of variation. These techniques include examining genomics, transcriptomics, 
epigenomics, proteomics, ncRNomics, interactomics, metabolomics, glycomics, 
lipidomics, phenomics, environmental-omics, pharmacogenomics, and integromics. 
 
Implications for Drug Development and Treatment 
The heterogeneity of clinical symptoms seen after diagnosis and those proposed 
as occurring during the pre-diagnostic phase suggests that identifying subtypes of PD is 
critical to the development of pre-diagnostic markers. The presence of distinct subtypes 
may suggest that what we currently call PD is actually a group of disorders rather than 
one complex disease. This concept has already produced similar shifts in oncology 
research and has been proposed as a hypothesis for better understanding Alzheimer’s 
disease (AD). While some have postulated that therapeutic trials in AD have failed by 
intervening too late in the neurodegenerative process, this hypothesis would suggest that 
therapies may need to be personalized for the various subtypes and underlying pathology 
specific to each disease subtype (Au, Piers, & Lancashire, 2015). Analogous problems 
may be hampering progress for treatments in PD, calling for more work in biomarker-




Even with well characterized subtypes of PD, individuals at risk will need to be 
identified in the earliest stages in order for disease-modifying or neuroprotective 
interventions to be effective (Espay et al., 2017). Since its introduction in 1961, levodopa 
has remained the gold standard in treatment for PD (Hornykiewicz, 2010), and most other 
treatments likewise focus on motor symptoms of the disease. Until recently, non-motor 
symptoms have been conspicuously neglected in treatment research (Cronin-Golomb, 
2013; Chaudhuri et al., 2011). Given the importance of non-motor symptoms to the pre-
diagnostic phase of PD, understanding treatment of these symptoms may be important in 
identifying and developing new therapies for PD overall. 
Depression and other non-motor symptoms do not reliably respond to 
dopaminergic therapy in PD and will require the identification of other treatment targets. 
(Schapira, Chaudhuri, & Jenner, 2017). In the case of depression, psychotropic 
medications may exacerbate PD symptoms or interact harmfully with dopaminergic 
therapies (Connolly & Fox, 2012). Non-pharmacologic treatments may provide options 
for the treatment of non-motor symptoms. Cognitive-behavioral therapy (CBT) has 
showed promise in reducing symptoms of both anxiety and depression in PD (Armento et 
al., 2012; Reynolds et al., 2018, submitted). Light therapy and CBT for insomnia may 
improve symptoms of sleep dysfunction in individuals with PD (Romenets et al., 2013). 
Exercise interventions have emerged as a treatment in PD that may improve non-motor 
symptoms including mood, cognition, and sleep, while also reducing motor symptoms 
(Reynolds et al., 2016). Physical activity and exercise have been shown to lead to reduce 




Klegeris, 2016). A review of exercise trials in PD has cited evidence for improved 
cognitive outcomes (da Silva et al., 2018).  
As described above, non-motor symptoms of PD have been shown to impact each 
other in a variety of ways, and causality, directionality, and mediating factors of these 
relations are not well understood. For example, exercise may improve cognition in PD by 
way of reduced inflammation, improved mood, improved sleep, or a combination of all 
three. Similarly, cognitive deficits in PD may be caused by low mood, poor sleep, or 
increased inflammation. The significant relations seen between these features of PD 
speak to the etiologic complexity of this disorder; a better understanding of where and 
when the neuropathology spreads may help us to establish the primacy of symptoms and 
the common and divergent points of their pathogenesis. It is likely that cognition, mood, 
and inflammation interact with each other and other non-motor symptoms as the pre-
diagnostic phase of PD progresses to conversion to clinical PD. 
 
Conclusion 
The current set of studies has contributed significantly to our understanding of the 
early development of PD in its use of prospective data from a community-based sample 
to examine pre-diagnostic risk factors. Studies 1, 2, and 3 examined cognition, 
depression, and inflammation, respectively, to determine their utility as potential pre-
diagnostic markers for the disease. Although the findings did not support the overall 
hypothesis that those who converted to PD would be different from non-converters in 




further research away from these particular potential pre-diagnostic markers of PD and 
toward others that may better inform the development of future research and clinical 
trials. 
This work emphasizes the increasing need for research and clinical focus on non-
motor symptoms in PD, as well as examination of the pre-diagnostic stages of the 
disease. With advancing knowledge on proposed markers, the field will be prepared to 
identify individuals in the early, pre-motor stages of PD appropriate for trials of 
neuroprotective therapies, with the goal of attenuating the rate of progress of the disease 
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